Prospective-Retrospective Analysis of PTEN Immunohistochemistry Assay for Prediction of Outcomes in Recurrent and Metastatic Prostate Cancer

Abstract

As part of the CDMRP-funded Precision Medicine Biomarker Validating Center, we have developed a robust, highly analytically validated and cost-effective immunohistochemistry (IHC)-based assay to interrogate PTEN loss in prostate cancer. Our PTEN assay is prognostic in multiple cohorts of surgically-treated prostate cancer patients; now, we propose to leverage this body of previous validation studies to test the hypothesis that PTEN loss in primary prostate cancer predicts for a less robust response to hormonal therapies, in the context of two recent, practice-changing Phase III clinical trials for which we have CTEP approval to access specimens. Here, we report on progress to date. We have obtained and immunostained slides from ECOG3805 (CHAARTED) for PTEN. In analyses, we have examined the association of PTEN loss with outcomes in the androgen deprivation therapy(ADT) arm (n=119) and the ADT+Docetaxel arm (n=108). We find that PTEN loss is not a significant predictor overall survival in the trial as a whole and is actually protective in the setting of high volume metastatic disease.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2018
Accession Number
AD1071924

Entities

People

  • Tamara L Lotan

Organizations

  • Johns Hopkins University

Tags

DTIC Thesaurus Topics

  • Androgens
  • Biological Markers
  • Biomedical Research
  • Clinical Trials
  • Data Analysis
  • Demographic Cohorts
  • Deprivation
  • Diseases And Disorders
  • Immunohistochemistry
  • Medical Personnel
  • Neoplasms
  • Personalized Medicine
  • Prostate
  • Prostate Cancer
  • Statistical Analysis
  • Survival
  • Tissues

Fields of Study

  • Medicine

Readers

  • Gulf War Illness and Chronic Multisymptom Illness in Veterans.
  • Oncology and Biomarker-Based Cancer Detection.
  • Prostate Cancer Biology.